Pricing Log in Create free account

NewAmsterdam Pharma Company N.V. (NAMS) vs Replimune Group, Inc. (REPL)

NewAmsterdam Pharma Company N.V. and Replimune Group, Inc. are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and Replimune Group, Inc. are of similar size ($2.3B and $2.2B). Replimune Group, Inc. has the higher net margin (0.00% vs −789.9%) and the higher return on invested capital (−928.3% vs −13,975.8%). Across the 14 metrics below, NewAmsterdam Pharma Company N.V. leads on 9 and Replimune Group, Inc. on 5.

Valuation

Metric NAMS REPL Biotechnology median
P/E n/m n/m 11.58
P/S 98.69 n/m 9.61
P/B 4.06 11.24 2.26
Price to free cash flow n/m n/m 26.41
EV/EBITDA n/m n/m 0.72
EV/Sales 74.41 n/m 9.43
Earnings yield (8.20%) (12.77%) (32.28%)
Free cash flow yield (5.89%) (10.68%) (22.27%)

Profitability

Metric NAMS REPL Biotechnology median
Gross margin 100.00% 0.00% 68.81%
Operating margin (900.07%) 0.00% 0.00%
Net margin (789.94%) 0.00% 0.00%
Free cash flow margin (581.64%) 0.00% 0.00%
Return on equity (30.16%) (115.80%) (50.30%)
Return on assets (27.79%) (71.01%) (45.47%)
Return on invested capital (13,975.75%) (928.27%) 0.00%

Growth

Metric NAMS REPL Biotechnology median
Revenue growth (TTM) (26.41%) — 6.78%
EPS growth (last fiscal year) 32.81% (10.10%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAMS REPL Biotechnology median
Debt to equity 0.00 0.59 0.00
Current ratio 11.76 7.11 4.74
Net debt to EBITDA 2.83 0.51 1.01

Dividend

Metric NAMS REPL Biotechnology median
Dividend yield — — 0.39%
Payout ratio — — —

Size

Metric NAMS REPL Biotechnology median
Market cap 2.30b 2.21b 168.63m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack